Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S., . . . Minckwitz, G. v. (2021). Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer: The Penelope-B trial. Journal of clinical oncology, 39(14), . https://doi.org/10.1200/JCO.20.03639
Chicago-Zitierstil (17. Ausg.)Loibl, Sibylle, et al. "Palbociclib for Residual High-risk Invasive HR-positive and HER2-negative Early Breast Cancer: The Penelope-B Trial." Journal of Clinical Oncology 39, no. 14 (2021). https://doi.org/10.1200/JCO.20.03639.
MLA-Zitierstil (9. Ausg.)Loibl, Sibylle, et al. "Palbociclib for Residual High-risk Invasive HR-positive and HER2-negative Early Breast Cancer: The Penelope-B Trial." Journal of Clinical Oncology, vol. 39, no. 14, 2021, https://doi.org/10.1200/JCO.20.03639.